A three-dimensional immunocompetent intestine-on-chip model as in vitro platform for functional and microbial interaction studies.


Journal

Biomaterials
ISSN: 1878-5905
Titre abrégé: Biomaterials
Pays: Netherlands
ID NLM: 8100316

Informations de publication

Date de publication:
11 2019
Historique:
received: 14 05 2019
revised: 08 07 2019
accepted: 28 07 2019
pubmed: 10 8 2019
medline: 21 10 2020
entrez: 10 8 2019
Statut: ppublish

Résumé

Alterations of the microbial composition in the gut and the concomitant dysregulation of the mucosal immune response are associated with the pathogenesis of opportunistic infections, chronic inflammation, and inflammatory bowel disease. To create a platform for the investigation of the underlying mechanisms, we established a three-dimensional microphysiological model of the human intestine. This model resembles organotypic microanatomical structures and includes tissue resident innate immune cells exhibiting features of mucosal macrophages and dendritic cells. The model displays the physiological immune tolerance of the intestinal lumen to microbial-associated molecular patterns and can, therefore, be colonised with living microorganisms. Functional studies on microbial interaction between probiotic Lactobacillus rhamnosus and the opportunistic pathogen Candida albicans show that pre-colonization of the intestinal lumen of the model by L. rhamnosus reduces C. albicans-induced tissue damage, lowers its translocation, and limits fungal burden. We demonstrate that microbial interactions can be efficiently investigated using the in vitro model creating a more physiological and immunocompetent microenvironment. The intestinal model allows a detailed characterisation of the immune response, microbial pathogenicity mechanisms, and quantification of cellular dysfunction attributed to alterations in the microbial composition.

Identifiants

pubmed: 31398556
pii: S0142-9612(19)30495-8
doi: 10.1016/j.biomaterials.2019.119396
pii:
doi:

Substances chimiques

Antigens, CD 0
Biomarkers 0
Cadherins 0
Cytokines 0
Lipopolysaccharides 0
Zonula Occludens-1 Protein 0
cadherin 5 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

119396

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Michelle Maurer (M)

Center for Sepsis Control and Care, Jena University Hospital, Friedrich-Schiller-University of Jena, Jena, Germany; Institute of Biochemistry II, Jena University Hospital, Jena, Germany.

Mark S Gresnigt (MS)

Department of Microbial Pathogenicity Mechanisms, Leibniz Institute for Natural Product Research and Infection Biology - Hans-Knoell-Institute, Jena, Germany.

Antonia Last (A)

Department of Microbial Pathogenicity Mechanisms, Leibniz Institute for Natural Product Research and Infection Biology - Hans-Knoell-Institute, Jena, Germany.

Tony Wollny (T)

Institute of Biochemistry II, Jena University Hospital, Jena, Germany.

Florian Berlinghof (F)

Institute of Biochemistry II, Jena University Hospital, Jena, Germany.

Rebecca Pospich (R)

Research Group Microbial Immunology, Leibniz Institute for Natural Product Research and Infection Biology-Hans Knoell Institute, Jena, Germany; Division of Immunodermatology and Allergy Research, Hannover Medical School, Hannover, Germany.

Zoltan Cseresnyes (Z)

Research Group Applied Systems Biology, Leibniz Institute for Natural Product Research and Infection Biology (HKI), Jena, Germany.

Anna Medyukhina (A)

Research Group Applied Systems Biology, Leibniz Institute for Natural Product Research and Infection Biology (HKI), Jena, Germany.

Katja Graf (K)

Department of Microbial Pathogenicity Mechanisms, Leibniz Institute for Natural Product Research and Infection Biology - Hans-Knoell-Institute, Jena, Germany.

Marko Gröger (M)

Center for Sepsis Control and Care, Jena University Hospital, Friedrich-Schiller-University of Jena, Jena, Germany; University of California, UCSF Broad Center of Regeneration Medicine and Stem Cell Research, San Francisco, USA.

Martin Raasch (M)

Center for Sepsis Control and Care, Jena University Hospital, Friedrich-Schiller-University of Jena, Jena, Germany; Institute of Biochemistry II, Jena University Hospital, Jena, Germany.

Fatina Siwczak (F)

Center for Sepsis Control and Care, Jena University Hospital, Friedrich-Schiller-University of Jena, Jena, Germany.

Sandor Nietzsche (S)

Centre for Electron Microscopy, Jena University Hospital, Friedrich-Schiller-University of Jena, Jena, Germany.

Ilse D Jacobsen (ID)

Center for Sepsis Control and Care, Jena University Hospital, Friedrich-Schiller-University of Jena, Jena, Germany; Research Group Microbial Immunology, Leibniz Institute for Natural Product Research and Infection Biology-Hans Knoell Institute, Jena, Germany; Institute of Microbiology, Faculty of Biological Sciences, Friedrich Schiller University, Jena, Germany.

Marc Thilo Figge (MT)

Research Group Applied Systems Biology, Leibniz Institute for Natural Product Research and Infection Biology (HKI), Jena, Germany; Institute of Microbiology, Faculty of Biological Sciences, Friedrich Schiller University, Jena, Germany.

Bernhard Hube (B)

Department of Microbial Pathogenicity Mechanisms, Leibniz Institute for Natural Product Research and Infection Biology - Hans-Knoell-Institute, Jena, Germany; Institute of Microbiology, Faculty of Biological Sciences, Friedrich Schiller University, Jena, Germany.

Otmar Huber (O)

Center for Sepsis Control and Care, Jena University Hospital, Friedrich-Schiller-University of Jena, Jena, Germany; Institute of Biochemistry II, Jena University Hospital, Jena, Germany.

Alexander S Mosig (AS)

Center for Sepsis Control and Care, Jena University Hospital, Friedrich-Schiller-University of Jena, Jena, Germany; Institute of Biochemistry II, Jena University Hospital, Jena, Germany. Electronic address: alexander.mosig@med.uni-jena.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH